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OBJECTIVE—YKL-40 is produced by macrophages, and plasma
YKL-40 is elevated in patients with diseases characterized by
inﬂammation. In the present study, YKL-40 was examined in
relation to obesity, inﬂammation, and type 2 diabetes.
RESEARCH DESIGN AND METHODS—Plasma YKL-40 and
adipose tissue YKL-40 mRNA levels were investigated in 199
subjects who were divided into four groups depending on the
presence or absence of type 2 diabetes and obesity. In addition,
plasma YKL-40 was examined in healthy subjects during a
hyperglycemic clamp, in which the plasma glucose level was
kept at 15 mmol/l for 3 h, and during a hyperinsulinemic-
euglycemic clamp.
RESULTS—Patients with type 2 diabetes had higher plasma
YKL-40 (76.7 vs. 45.1 ng/ml, P  0.0001) but not higher expression
in adipose tissue YKL-40 mRNA (1.20 vs. 0.98, P  0.2) compared
with subjects with a normal glucose tolerance. Within the groups
with normal glucose tolerance and type 2 diabetes, obesity
subgroups showed no difference with respect to either plasma
YKL-40 or adipose tissue YKL-40 mRNA levels. Multivariate
regression analysis showed that plasma YKL-40 was associated
with fasting plasma glucose (0.5, P  0.0014) and plasma
interleukin (IL)-6 (0.2, P  0.0303). Plasma YKL-40 was not
related to parameters of obesity. There were no changes in
plasma YKL-40 in healthy subjects during either hyperglycemic
or hyperinsulinemic-euglycemic clamps.
CONCLUSIONS—Plasma YKL-40 was identiﬁed as an obesity-
independent marker of type 2 diabetes related to fasting plasma
glucose and plasma IL-6 levels. Diabetes 57:3078–3082, 2008
Y
KL-40 (chitinase-3-like-1 [CHI3L1], human carti-
lage glycoprotein-39), is a heparin-, chitin-, and
collagen-binding lectin produced by immunolog-
ically active cells such as macrophages (1) and
neutrophils (2). YKL-40 is a member of the mammalian
chitinase-like proteins and is a phylogenetically highly
conserved serum protein (1,3–5). Other cells shown to
produce YKL-40 are vascular smooth muscle and endothe-
lia cells (6–8), arthritic chondrocytes (3), cancer cells (9),
and embryonic and fetal cells (10). The exact functions of
YKL-40 are unknown. Currently, YKL-40 is known to
stimulate growth of ﬁbroblast cells (11), activate the AKT
and phosphoinositide-3 kinase signaling pathway, exert
antiapoptosis (12), and function in angiogenesis (7) and
may take part in the innate immune response (13). High
plasma concentrations of YKL-40 are found in patients
with diseases characterized by inﬂammation or increased
tissue remodeling or with cancer (1,9).
Adipose tissue is recognized as a source of inﬂammation
(14–16). A high BMI is associated with increased levels of
proinﬂammatory cytokines, and obesity is characterized
as a state of chronic systemic low-grade inﬂammation
(17). Studies demonstrate an accumulation of activated
macrophages and other immune active cells in adipose
tissue from obese subjects (17,18) as possible sources of
inﬂammatory cytokines, determining a link between obe-
sity, low-grade inﬂammation, and insulin resistance, and
both obesity and low-grade inﬂammation have been linked
with the development of insulin resistance and type 2
diabetes (19).
One previous study (20) has shown an elevation of
serum YKL-40 in type 2 diabetes. In the present study,
using plasma and adipose tissue biopsy material from 103
healthy control subjects and 96 patients with type 2
diabetes with a wide range of BMI, we studied the possible
relationship between plasma YKL-40 and adipose tissue
expression of YKL-40 on the one hand and obesity, insulin
resistance, and inﬂammation on the other.
We further measured the macrophage marker CD68 in
adipose tissue. We hypothesized that macrophages in the
adipose tissue might secrete YKL-40 and that plasma
YKL-40 would represent macrophage inﬁltration in adi-
pose tissue and serve as a marker of insulin resistance. In
order to obtain further information about the regulation of
systemic YKL-40, we examined plasma YKL-40 during hy-
perglycemic and hyperinsulinemic-euglycemic conditions.
RESEARCH DESIGN AND METHODS
Cohort study. Using a cross-sectional, case-control design, the participants
in this study were divided into four distinct groups according to BMI (30 or
30 kg/m
2) and according to normal glucose tolerance and the diagnosis of
type 2 diabetes. To verify correct diagnosis, an oral glucose tolerance test was
performed and the World Health Organization diagnostic criteria for diabetes
were used. Participants were carefully screened, and exclusion criteria were
treatment with insulin, recent or ongoing infection, history of malignant
disease, or treatment with anti-inﬂammatory drugs. Subjects and protocol
have been previously described (21,22). Participants (n  199) were given
both oral and written information about the experimental procedures before
giving their written informed consent.
Subjects. Participants reported to the laboratory between 8 and 10 A.M. after
an overnight fast. Medication was paused for 24 h and oral antidiabetes
medication for 1 week before the examination day. A general health exami-
nation was performed; blood samples were drawn from an antecubital vein,
adipose tissue biopsy was obtained, an oral glucose tolerance test and a
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3078 DIABETES, VOL. 57, NOVEMBER 2008ﬁtness test were performed (cardiorespiratory ﬁtness was measured by the
Åstrand-Rhyming indirect test of maximal oxygen uptake [VO2max]) (23), and
subjects were scanned on a dual-energy X-ray absorptiometry whole-body
scanner, as previously described (21,22).
Blood analysis. Plasma concentrations of YKL-40 were determined in dupli-
cate by a commercial enzyme-linked immunosorbent assay (Quidel, San
Diego, CA) (24). The recovery is 102%, detection limit 20 g/l, intra-assay
coefﬁcient of variation  5.0%, and interassay coefﬁcient of variation 6.3%.
Plasma concentrations of tumor necrosis factor (TNF)- (intra- and interassay
coefﬁcient of variation 8.8 and 16.7%, respectively) and interleukin (IL)-6
(intra- and interassay coefﬁcient of variation 6.9 and 9.6%, repectively) were
measured by enzyme-linked immunosorbent assay (R&D Systems, Minneap-
olis, MN). Plasma C-reactive protein (intra- and interassay coefﬁcient of
variation 2.8 and 4.6%, respectively) was measured at the Department of
Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark, using Tina-
quant CRPLX (Roche Diagnostics, Mannheim, Germany). Other measure-
ments have been previously described (21,22).
Adipose tissue YKL-40 mRNA and CD68 mRNA. Adipose tissue biopsies
were obtained from abdominal subcutaneous adipose tissue, as previously
described (22). Real-time PCR was performed using predeveloped TaqMan
assays (Applied Biosystems, Foster City, CA) for YKL-40 (Hs00542562_m1),
CD68 (Hs00154355_m1), and endogenous control glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) (Hs99999905_m1). The mRNA content of both
targets and GAPDH were calculated from the cycle threshold values using the
standard curve method, and relative expression of YKL-40 and CD68 were
determined after normalization to GAPDH. Not all tissue samples resulted in
a sufﬁcient amount of cDNA for all analysis, explaining the difference in
sample size, as indicated in Fig. 1.
Clamp study. Seven healthy men (mean age 26.7 years [range 23–34]; mean
BMI 23.7 kg/m
2 [21.2–27.7]) were included, following provision of oral and
written informed consent. Before the study, the subjects underwent a clinical
examination as previously described (21). All subjects underwent two sepa-
rate trials at least 1 month apart. One trial comprised a steady-state hypergly-
cemic clamp (blood glucose clamped at 15 mmol/l) and the other a
hyperinsulinemic-euglycemic clamp (blood glucose clamped at 5 mmol/l) in
combination with an insulin infusion of 80 mU  min
1  m
2.
Ethics. The studies conformed to the Helsinki Declaration and were approved
by the ethics committee of Copenhagen and Frederiksberg, Denmark (KF
01-141/04 and 01-257245).
Statistics. Plasma levels of homeostasis model assessment, version 2
(HOMA2), YKL-40, adipose tissue YKL-40 mRNA, and CD68 mRNA were log
10
transformed to approximate normal distribution. Differences between glyce-
mia and obesity groups were tested with a two-way ANOVA (PROC GLM).
Multiple regression analysis (PROC REG) was performed to identify whether
the level of BMI, parameters of inﬂammation, and type 2 diabetes (explanatory
variable) could explain the variation in plasma YKL-40 and adipose tissue
YKL-40 mRNA expression (dependent variable). Using a two-way ANOVA
(PROC MIXED), the effect of time and group was tested in the clamp study.
Normality of the residuals was assessed graphically. P  0.05 was
considered signiﬁcant. All analyses were performed with SAS 9.1 (SAS
Institute, Cary, NC).
RESULTS
Subject characteristics. The cohort has previously been
described (21). Characteristics of the four main groups
included in the present study are shown in Table 1. Plasma
YKL-40 within these four groups is shown in Fig. 1A.
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FIG. 1. A: Plasma concentrations of YKL-40 in the four groups (n 
196): normal glucose tolerance (NGT)/nonobese, NGT/obese, type 2
diabetes (T2DM)/nonobese, and T2DM/obese. B: YKL-40 mRNA/
GAPDH mRNA expression level in adipose tissue in the four groups
(n  159). C: CD68 mRNA/GAPDH mRNA expression level in adipose
tissue in the four groups (n  154). Data are presented as geometric
means  SE. Difference between glycemia group (NGT vs. T2DM), *P <
0.001.
TABLE 1
Subject characteristics
Normal glucose tolerance Type 2 diabetes
Nonobese Obese Nonobese Obese
n (male/female) 62 (42/20) 41 (28/13) 50 (38/12) 46 (34/12)
Age (years) 56  24 8  2† 58  25 8  1
BMI (kg/m
2) 25.7  0.4 36.7  0.7‡ 26.6  0.3 35.5  0.7‡
HOMA2 0.66 (0.60–0.70) 1.28 (1.09–1.38)‡ 1.22 (1.01–1.32) 2.27 (1.97–2.42)‡§
Data are means  SE for continuous variables and geometric means (limits for SE of geometric means), unless otherwise indicated. General
characteristics of the study population divided into four groups on the basis of obesity and diagnosis of type 2 diabetes. Normal glucose
tolerance/nonobese, normal glucose tolerance/obese, type 2 diabetes/nonobese, and type 2 diabetes/obese. Difference between obesity
groups within each glycemia group, †P  0.01; ‡P  0.001. Difference between glycemia group (normal glucose tolerance versus type 2
diabetes), §P  0.001. For age and BMI, there was an interaction between glycemia group and obesity.
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DIABETES, VOL. 57, NOVEMBER 2008 3079Plasma YKL-40 was increased in type 2 diabetic patients
compared with subjects with normal glucose tolerance,
independently of obesity (P  0.0001). The expression of
YKL-40 mRNA and CD68 mRNA in adipose tissue was not
different with regard to either glycemia group or obesity
(Fig. 1B and C). No interaction between obesity and
diabetes were found in plasma or mRNA analyses.
YKL-40 and type 2 diabetes
Plasma YKL-40. Univariate and multivariate regression
analyses with parameters of obesity, type 2 diabetes, and
inﬂammation as the explanatory variables and plasma
YKL-40 as the dependent variable, stratiﬁed or not accord-
ing to normal glucose tolerance/type 2 diabetes, are shown
in Table 2. In the multivariate analysis, we adjusted for
age, sex, ﬁtness, and either plasma TNF- or fasting
plasma glucose since these parameters were highly asso-
ciated with YKL-40 in the univariate analysis. No interac-
tions were found between glycemia group and the
explanatory variables, indicating that the slopes between
YKL-40 and the explanatory variables did not differ be-
tween subgroups with normal glucose tolerance and those
with type 2 diabetes. Therefore, here we focus on the
nonstratiﬁed analyses.
In univariate analysis, plasma YKL-40 was positively
associated with fasting plasma glucose (Fig. 2A), fasting
plasma insulin, HOMA2, A1C, plasma IL-6, and plasma
TNF-. After adjusting for age, sex, ﬁtness level, and either
TNF- or fasting plasma glucose, plasma YKL-40 was
positively associated with fasting plasma glucose (P 
0.0014) and plasma IL-6 (P  0.0303). There was a ten-
dency toward a positive association between plasma
YKL-40 and HOMA2 (P  0.0545). No association with
parameters of obesity was found. Age and ﬁtness level
showed separate associations with plasma YKL-40 (
0.01, P  0.0001 and  1.0, P  0.0001, respectively).
No interactions between the various covariates and these
confounders were found.
YKL-40 mRNA. Univariate and multivariate regression
analyses between YKL-40 mRNA in adipose tissue and
explanatory variables stratiﬁed or not into groups with
normal glucose tolerance and groups with type 2 diabetes
are presented in Table 3. As for plasma YKL-40, no
interaction was found between YKL-40 mRNA and explan-
atory variables. In the nonstratiﬁed univariate analysis,
there was an association between adipose tissue YKL-40
mRNA and plasma YKL-40 (P  0.0134), but this was not
present after adjustments. There was no association be-
tween adipose tissue CD68 mRNA and plasma YKL-40
(P  0.75).
Adipose tissue YKL-40 mRNA showed positive asso-
ciations with fasting plasma glucose, fasting plasma
insulin, HOMA2, and A1C and a tendency with plasma
C-reactive protein (P  0.0755). In multiple regression
analysis, positive associations were found with fasting
plasma insulin (P  0.0018) and HOMA2 (P  0.0011).
There was a tendency to a positive association between
YKL-40 mRNA and A1C (P  0.0645). No association
was found between adipose tissue YKL-40 mRNA ex-
pression and parameters of inﬂammation or parameters
of obesity.
YKL-40 during clamp. In healthy subjects,3ho fhyper-
glycemic clamp conditions or hyperinsulinemic-euglyce-
mic clamp conditions did not change plasma YKL-40 (Fig.
2B).
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PLASMA YKL-40 AND TYPE 2 DIABETES
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In the present study, we demonstrated that patients with
type 2 diabetes have elevated plasma YKL-40 compared
with healthy control subjects. In multivariate regression
analysis adjusted for age, sex, ﬁtness, and either plasma
TNF- or fasting plasma glucose, we found signiﬁcant
associations between plasma YKL-40 and fasting plasma
glucose and plasma IL-6 but no associations with param-
eters of obesity.
Plasma IL-6 and obesity (BMI) showed a strong positive
association (R
2  0.2, 7.9, P  0.0001). In addition, we
found a relationship between plasma IL-6 and plasma
YKL-40 but no association between YKL-40 and markers of
obesity. Ongoing studies in our laboratory show that acute
elevation of plasma IL-6 (by intravenous infusion) increase
plasma YKL-40 in humans. At ﬁrst glance, it seems para-
doxical that plasma YKL-40 is not related to obesity.
However, as is evident from Table 2A, plasma IL-6 can only
explain 3% of the variation in plasma YKL-40, indicating
that other factors may be more important for the produc-
tion/release of YKL-40. It is possible that acute changes in
plasma IL-6, as found in infections, can exert acute
changes in plasma YKL-40, whereas in type 2 diabetes,
characterized by low-grade inﬂammation, IL-6 may not be
the most important regulator of YKL-40.
The positive correlation between subcutaneous adipose
tissue YKL-40 mRNA and plasma YKL-40 support the idea
that adipose tissue contributes to circulating YKL-40.
Given that YKL-40 is produced by macrophages, it is
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FIG. 2. A: Association between fasting plasma glucose and plasma
YKL-40 levels in subjects with normal glucose tolerance (n  101) ()
and type 2 diabetes patients (n  95) (Œ). Logarithmic data are
presented. R
2  0.11. B: Changes in plasma YKL-40 in healthy subjects
during two different clamp conditions. Œ, plasma YKL-40 during hyper-
glycemic clamp (n  7). , plasma YKL-40 during hyperinsulinemic-
euglycemic clamp (n  7). Data are presented as means  SE.
T
A
B
L
E
3
A
d
i
p
o
s
e
t
i
s
s
u
e
Y
K
L
-
4
0
m
R
N
A
C
o
v
a
r
i
a
t
e
N
o
r
m
a
l
g
l
u
c
o
s
e
t
o
l
e
r
a
n
c
e
T
y
p
e
2
d
i
a
b
e
t
e
s
N
o
r
m
a
l
g
l
u
c
o
s
e
t
o
l
e
r
a
n
c
e
a
n
d
t
y
p
e
2
d
i
a
b
e
t
e
s
U
n
i
v
a
r
i
a
t
e
M
u
l
t
i
v
a
r
i
a
t
e
U
n
i
v
a
r
i
a
t
e
M
u
l
t
i
v
a
r
i
a
t
e
U
n
i
v
a
r
i
a
t
e
M
u
l
t
i
v
a
r
i
a
t
e

(
9
5
%
C
I
)
R
2
P

(
9
5
%
C
I
)
P

(
9
5
%
C
I
)
R
2
P

(
9
5
%
C
I
)
P

(
9
5
%
C
I
)
R
2
P

(
9
5
%
C
I
)
P
B
M
I
0
.
0
(

0
.
0
t
o
0
.
0
)
0
.
0
5
0
.
0
6
0
3
0
.
0
(

0
.
0
t
o
0
.
0
)
N
S

0
.
0
(

0
.
0
t
o
0
.
0
)
—
N
S
—
—
0
.
0
(

0
.
0
t
o
0
.
0
)
—
N
S
—
—
G
l
u
c
o
s
e
(
0
h
)

0
.
0
(

3
.
0
t
o
3
.
0
)
—
N
S
—
—
0
.
7
(

0
.
0
t
o
1
.
4
)
0
.
0
5
0
.
0
5
6
9
0
.
5
(

0
.
2
t
o
1
.
2
)
N
S
0
.
5
(
0
.
1
–
1
.
0
)
0
.
0
3
*
0
.
4
(

0
.
1
t
o
1
.
0
)
N
S
I
n
s
u
l
i
n
(
0
h
)
0
.
4
(
0
.
1
–
0
.
8
)
0
.
0
6
*
0
.
5
(
0
.
0
–
1
.
0
)
*
0
.
4
(
0
.
0
–
0
.
7
)
0
.
0
6
*
0
.
4
(
0
.
0
–
0
.
7
)
*
0
.
4
(
0
.
2
–
0
.
7
)
0
.
0
7
†
0
.
5
(
0
.
2
–
0
.
7
)
‡
H
O
M
A
2
0
.
4
(
0
.
0
–
0
.
8
)
0
.
0
6
*
0
.
5
(
0
.
0
–
1
.
0
)
*
0
.
4
(
0
.
1
–
0
.
7
)
0
.
0
8
*
0
.
4
(
0
.
1
–
0
.
7
)
N
S
0
.
4
(
0
.
2
–
0
.
7
)
0
.
0
8
†
0
.
5
(
0
.
2
–
0
.
7
)
‡
A
1
C

1
.
2
(

8
.
0
t
o
5
.
5
)
—
N
S
—
—
1
.
3
(
0
.
0
–
2
.
5
)
0
.
0
5
*
1
.
0
(

0
.
3
t
o
2
.
2
)
—
1
.
2
(
0
.
2
–
2
.
1
)
0
.
0
4
*
1
.
0
(

0
.
1
t
o
2
.
0
)
0
.
0
6
4
5
I
L
-
6
0
.
2
(

0
.
2
t
o
0
.
5
)
—
N
S
—
—
0
.
0
(

0
.
4
t
o
0
.
4
)
—
N
S
—
—
0
.
1
(

0
.
1
t
o
0
.
4
)
—
N
S
—
—
T
N
F
-


0
.
5
(

1
.
8
t
o
0
.
9
)
—
N
S
—
—
1
.
0
(
0
.
1
–
1
.
9
)
0
.
0
6
*
0
.
9
(

0
.
0
t
o
1
.
9
)
0
.
0
6
2
2
0
.
6
(

0
.
1
t
o
1
.
3
)
—
N
S
—
—
C
-
r
e
a
c
t
i
v
e
p
r
o
t
e
i
n
0
.
3
(
0
.
0
–
0
.
6
)
0
.
0
6
*
0
.
3
(

0
.
1
t
o
0
.
6
)
N
S
0
.
0
(

0
.
3
t
o
0
.
3
)
—
N
S
—
—
0
.
2
(

0
.
0
t
o
0
.
4
)
0
.
0
2
0
.
0
7
5
5
0
.
2
(

0
.
1
t
o
0
.
4
)
N
S
U
n
i
v
a
r
i
a
t
e
a
n
d
m
u
l
t
i
v
a
r
i
a
t
e
r
e
g
r
e
s
s
i
o
n
a
n
a
l
y
s
e
s
w
i
t
h
p
a
r
a
m
e
t
e
r
s
f
o
r
t
y
p
e
2
d
i
a
b
e
t
e
s
,
i
n
ﬂ
a
m
m
a
t
i
o
n
,
a
n
d
B
M
I
a
s
p
r
e
d
i
c
t
o
r
s
o
f
p
l
a
s
m
a
Y
K
L
-
4
0
a
n
d
a
d
i
p
o
s
e
t
i
s
s
u
e
Y
K
L
-
4
0
m
R
N
A
e
x
p
r
e
s
s
i
o
n
.
B
o
t
h
Y
K
L
-
4
0
a
n
d
a
l
l
c
o
v
a
r
i
a
t
e
m
e
a
s
u
r
e
m
e
n
t
s
(
e
x
c
e
p
t
B
M
I
)
w
e
r
e
l
o
g
1
0
t
r
a
n
s
f
o
r
m
e
d
,
a
n
d
a
1
-
u
n
i
t
i
n
c
r
e
a
s
e
,
h
e
n
c
e
,
s
i
g
n
i
ﬁ
e
s
a
1
0
-
f
o
l
d
i
n
c
r
e
a
s
e
.
M
u
l
t
i
v
a
r
i
a
t
e
a
n
a
l
y
s
e
s
w
e
r
e
a
d
j
u
s
t
e
d
f
o
r
a
g
e
(
y
e
a
r
s
)
,
s
e
x
(
m
a
l
e
/
f
e
m
a
l
e
)
,
ﬁ
t
n
e
s
s
[
l
o
g
(
V
o
2

k
g

1

f
a
t
f
r
e
e
m
a
s
s

1
)
]
,
a
n
d
e
i
t
h
e
r
p
l
a
s
m
a
T
N
F
-

(
g
l
u
c
o
s
e

0
h
	
,
i
n
s
u
l
i
n

0
h
	
,
H
O
M
A
2
,
a
n
d
A
1
C
)
,
o
r
f
a
s
t
i
n
g
p
l
a
s
m
a
g
l
u
c
o
s
e
(
I
L
-
6
,
T
N
F
-

,
a
n
d
C
-
r
e
a
c
t
i
v
e
p
r
o
t
e
i
n
)
.
*
P

0
.
0
5
;
†
P

0
.
0
1
;
‡
P

0
.
0
0
1
.
N
S
,
n
o
t
s
i
g
n
i
ﬁ
c
a
n
t
.
A.R. NIELSEN AND ASSOCIATES
DIABETES, VOL. 57, NOVEMBER 2008 3081surprising that CD68 mRNA expression in adipose tissue
did not correlate with plasma YKL-40. However, YKL-40
may only be produced by a subgroup of macrophages
(CD14

 and CD16

) in adipose tissue, as seen in other
diseases (1), in contrast with CD68, which is produced by
all monocytes and macrophages. Studying adipose tissue
biopsies, we were not able to distinguish between the
roles of macrophages and, for example, endothelial cells
or smooth muscle cells with regard to the production of
YKL-40. It cannot be excluded that adipose tissue is a
source of YKL-40 production, though the production of
YKL-40 may be attributed to different cells. Furthermore,
visceral adipose tissue is more inﬂamed than subcutane-
ous adipose tissue and is a possible source of plasma
YKL-40, but our study design did not allow for the illumi-
nation of the role of visceral fat.
The precise role of YKL-40 remains elusive, but our
ﬁndings suggest that YKL-40 might be involved in metab-
olism. However, here we demonstrate that YKL-40 levels
do not ﬂuctuate with acute changes in plasma glucose or
plasma insulin. Studies are needed to determine the role of
adipocytes, macrophages, smooth muscle, and endothelial
cells as sources of YKL-40 in adipose tissue and to clarify
whether YKL-40 is directly involved in the pathophysiology
of type 2 diabetes or may be a more general marker of
inﬂammation. In conclusion, we identify plasma YKL-40 as
an obesity-independent marker of type 2 diabetes that is
positively associated with fasting plasma glucose and
plasma IL-6 level.
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